Departments of Radiology, Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
AJNR Am J Neuroradiol. 2013 Jun-Jul;34(6):1197-202. doi: 10.3174/ajnr.A3369. Epub 2012 Dec 28.
APOE4 is the best-documented genetic risk factor for sporadic AD. Previous research showed that APOE4 is associated with increased risk of occurrence and earlier onset of AD in a gene dose-dependent manner. However, the specific role of APOE4 in processing of brain functions requires further investigation. Investigators have used fMRI to measure brain activity on the basis of the blood oxygen level-dependent contrast. This study investigates the effects of APOE4 on fMRI during n-back WM tasks in healthy middle-aged adults.
From 110 participants, 81 individuals without objective or subjective cognitive impairment underwent APOE genotyping. Nine APOE4 carriers and 9 age- and sex-matched non-APOE4 controls were recruited for fMRI examinations during WM tasks.
Both groups displayed increased brain activation in response to increases in WM loads. During low-WM-load tasks, the APOE4 carriers recruited significantly greater additional processing resources than the non-APOE4 carriers. During moderate- and high-WM-load tasks, the APOE4 carrier group displayed fewer increases in activation than the non-APOE4 carrier group.
APOE genetic polymorphisms may affect brain functioning in subjects without dementia. The patterns of brain activation during different levels of WM load suggest possible subclinical impairment of WM capacity in APOE4 carriers (ClinicalTrials.gov registration: NCT01287819).
APOE4 是散发性 AD 最具文献记载的遗传风险因素。先前的研究表明,APOE4 以基因剂量依赖的方式与 AD 的发病风险增加和发病年龄提前有关。然而,APOE4 在大脑功能处理中的具体作用需要进一步研究。研究人员已经使用 fMRI 基于血氧水平依赖对比来测量大脑活动。本研究调查了 APOE4 对健康中年成年人执行 n-back WM 任务时 fMRI 的影响。
从 110 名参与者中,81 名无客观或主观认知障碍的个体接受了 APOE 基因分型。招募了 9 名 APOE4 携带者和 9 名年龄和性别匹配的非 APOE4 对照者进行 WM 任务期间的 fMRI 检查。
两组在 WM 负荷增加时均显示出大脑激活增加。在低 WM 负荷任务中,APOE4 携带者比非 APOE4 携带者招募的额外处理资源显著增加。在中高 WM 负荷任务中,APOE4 携带者组的激活增加幅度小于非 APOE4 携带者组。
APOE 遗传多态性可能影响无痴呆症受试者的大脑功能。不同 WM 负荷水平下的大脑激活模式表明 APOE4 携带者的 WM 容量可能存在亚临床损害(ClinicalTrials.gov 注册号:NCT01287819)。